Features and properties of viral and non-viral gene delivery systems towards effective gene therapy

 
 
 
  • Abstract
  • Keywords
  • References
  • PDF
  • Abstract


    Gene therapy has revolutionized the treatment of hereditary and genetic link disorders by consciously swapping, fixing, adding or deleting the genetic sequences responsible for the condition. The culprit cells are altered by inserting purposeful genes and incorporated into their genome for proper expression. Germ line therapy ensures the genotypic changes to be transferred to the next generation (offspring) while the somatic type adequately rest on corrective pedestals and as such not advantageous to the offspring. The earlier was constrained by technical difficulties as well as ethical consideration. The accomplishment of the therapeutic benefits of gene therapy requires a special ferry system “vectors”. Vectors are designed to transfer the desired gene into its target cell without exposing it to some degrading enzymes, and must allow transcription to successfully take place. A model vector must not be immunogenic, it must not trigger high immune response detrimental to the patient and a specific tropism must be a pre-requisite. The choice of a vector should be based on safety, cost and availability as well as the accessibility of possible options. Mainly for viral carriers, host immune response trigger are the main concern. Viral vectors most frequently used in gene therapy include adenoviruses, retroviruses, poxviruses, adeno-associated viruses and herpes simplex viruses.


  • Keywords


    Gene Therapy; Germ Line; Somatic; Viral Vectors; Non-Viral Vectors; Ethics.

  • References


      [1] Wirth, T., Parker, N. and Ylä-Herttuala, S. (2013) History of gene therapy. Gene [online], 525:2, 162-169 https://doi.org/10.1016/j.gene.2013.03.137.

      [2] Amer, M.H. (2014) Gene therapy for cancer: present status and future perspective. Molecular and Cellular Therapies [online], 2(1), pp. 27. https://doi.org/10.1186/2052-8426-2-27.

      [3] Katare, D.P. and Aeri, V. (2010) Progress in gene therapy: A Review. IJTPR [online], 1pp. 33-41.

      [4] Dunlop, M.G., 1997. Gene Therapy. Edited by NR Lemoine and DN Cooper. Bios Scientific Publishers, 1996.

      [5] Lundstrom, K. (2003) Latest development in viral vectors for gene therapy. Trends in biotechnology [online], 21(3), pp. 117-122. https://doi.org/10.1016/S0167-7799(02)00042-2.

      [6] Mali, S. (2013) Delivery systems for gene therapy. Indian journal of human genetics [online], 19(1), pp. 3. https://doi.org/10.4103/0971-6866.112870.

      [7] Check, E. (2002) Gene therapy: a tragic setback. Nature [online], 420(6912), pp. 116-118. https://doi.org/10.1038/420116a.

      [8] Patil, P., Chaudharie, P., Sahu, M. and Duragkar, J. (2012) Review article on gene therapy. Int J Genetics [online], 4(1), pp. 74-79. https://doi.org/10.9735/0975-2862.4.1.74-79.

      [9] Dunlop, C.E., Telfer, E.E. and Anderson, R.A. (2014) ovarian germline stem cells. Stem Cell Res Ther [online], 5(98), pp. 10.1186. https://doi.org/10.1186/scrt487.

      [10] Misra, S. (2013) Human gene therapy: a brief overview of the genetic revolution. J Assoc Physicians India [online], 61(2), pp. 127-133.

      [11] Jones, D.A. (2015) the other woman: Evaluating the language of ‘three parent’embryos. Clinical Ethics [online], 10(4), pp. 97-106. https://doi.org/10.1177/1477750915599721.

      [12] Somia, N. and Verma, I.M. (2000) Gene therapy: trials and tribulations. Nature Reviews Genetics [online], 1(2), pp. 91-99. https://doi.org/10.1038/35038533.

      [13] Gardlik, R., Palffy, R., Hodosy, J., Lukacs, J., Turna, J. and Celec, P. (2005) Vectors and delivery systems in gene therapy. Medical science monitor: international medical journal of experimental and clinical research [online], 11(4), pp. RA110-21.

      [14] Bolhassani, A. and Rafati, S. (2011) Non-Viral Delivery Systems in Gene Therapy and Vaccine Development. [online] INTECH Open Access Publisher.

      [15] Ibraheem, D., Elaissari, A. and Fessi, H. (2014) Gene therapy and DNA delivery systems. International journal of pharmaceutics [online], 459(1), pp. 70-83. https://doi.org/10.1016/j.ijpharm.2013.11.041.

      [16] Kay, M.A., Glorioso, J.C. and Naldini, L. (2001) Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nature medicine [online], 7(1), pp. 33-40. https://doi.org/10.1038/83324.

      [17] Berk, A., Zipursky, S. and Lodish, H. (2000) Molecular Cell Biology 4th edition. [Online].

      [18] Walther, W. and Stein, U. (2000) Viral vectors for gene transfer. Drugs [online], 60(2), pp. 249-271. https://doi.org/10.2165/00003495-200060020-00002.

      [19] Stone, D. (2010) Novel viral vector systems for gene therapy. Viruses [online], 2(4), pp. 1002-1007. https://doi.org/10.3390/v2041002.

      [20] Raper, S.E., Chirmule, N., Lee, F.S., Wivel, N.A., Bagg, A., Gao, G., Wilson, J.M. and Batshaw, M.L. (2003) Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Molecular genetics and metabolism [online], 80(1), pp. 148-158. https://doi.org/10.1016/j.ymgme.2003.08.016.

      [21] ENDERS, J.F., BELL, J.A., DINGLE, J.H., FRANCIS, T.,Jr, HILLEMAN, M.R., HUEBNER, R.J. and PAYNE, A.M. (1956) Adenoviruses: group name proposed for new respiratory-tract viruses. Science (New York, N.Y.) [Online], 124(3212), pp. 119-120. https://doi.org/10.1126/science.124.3212.119.

      [22] Glasgow, J., Everts, M. and Curiel, D. (2006) Transductional targeting of adenovirus vectors for gene therapy. Cancer gene therapy [online], 13(9), pp. 830-844. https://doi.org/10.1038/sj.cgt.7700928.

      [23] Ginn, S.L., Alexander, I.E., Edelstein, M.L., Abedi, M.R. and Wixon, J. (2013) Gene therapy clinical trials worldwide to 2012–an update. The journal of gene medicine [online], 15(2), pp. 65-77. https://doi.org/10.1002/jgm.2698.

      [24] Saha, B., Wong, C.M. and Parks, R.J. (2014) The Adenovirus genome contributes to the structural stability of the virion. Viruses [online], 6(9), pp. 3563-3583. https://doi.org/10.3390/v6093563.

      [25] Monahan, P.E. and Samulski, R.J. (2000) Adeno-associated virus vectors for gene therapy: more pros than cons? Molecular medicine today [online], 6(11), pp. 433-440. https://doi.org/10.1016/S1357-4310(00)01810-4.

      [26] Jooss, K. and Chirmule, N. (2003) Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy. Gene therapy [online], 10(11), pp. 955-963. https://doi.org/10.1038/sj.gt.3302037.

      [27] Rabinowitz, J.E. and Samulski, R.J. (2000) Building a better vector: the manipulation of AAV virions. Virology [online], 278(2), pp. 301-308. https://doi.org/10.1006/viro.2000.0707.

      [28] Kimura, B., Mohuczy, D., Tang, X. and Phillips, M.I. (2001) Attenuation of hypertension and heart hypertrophy by adeno-associated virus delivering angiotensinogen antisense. Hypertension [online], 37(2 Pt 2), pp. 376-380. https://doi.org/10.1161/01.HYP.37.2.376.

      [29] Wang, A.Y., Peng, P.D., Ehrhardt, A., Storm, T.A. and Kay, M.A. (2004) Comparison of adenoviral and adeno-associated viral vectors for pancreatic gene delivery in vivo. Human Gene Therapy [online], 15(4), pp. 405-413. https://doi.org/10.1089/104303404322959551.

      [30] Anson, D.S. (2004) the use of retroviral vectors for gene therapy-what are the risks? A review of retroviral pathogenesis and its relevance to retroviral vector-mediated gene delivery. Genet Vaccines Ther [online], 2(9), pp. 1-13.

      [31] Verma, I.M. and Weitzman, M.D. (2005) Gene therapy: twenty-first century medicine. Annu.Rev.Biochem. [online], 74pp. 711-738. https://doi.org/10.1146/annurev.biochem.74.050304.091637.

      [32] Kaplitt, M.G., Darakchiev, B. and During, M.J. (1998) Prospects for gene therapy in pediatric neurosurgery. Pediatric neurosurgery [online], 28(1), pp. 3-14. https://doi.org/10.1159/000028611.

      [33] Shen, J., Huang, K.A., Chao-Yu, C., Chen, C., Lin, T. and Huang, Y. (2015) Seroprevalence of Herpes Simplex Virus Type 1 and 2 in Taiwan and Risk Factor Analysis, 2007. PloS one [online], 10(8), pp. e0134178. https://doi.org/10.1371/journal.pone.0134178.

      [34] Latchman, D.S. (2001) Gene delivery and gene therapy with herpes simplex virus-based vectors. Gene [online], 264(1), pp. 1-9. https://doi.org/10.1016/S0378-1119(01)00322-5.

      [35] Iizuka, S., Sakurai, F., Shimizu, K., Ohashi, K., Nakamura, S., Tachibana, M. and Mizuguchi, H. (2015) Evaluation of Transduction Properties of an Adenovirus Vector in Neonatal Mice. BioMed Research International [online], 2015. https://doi.org/10.1155/2015/685374.

      [36] Thomas, M. and Klibanov, A. (2003) Non-viral gene therapy: polycation-mediated DNA delivery. Applied Microbiology and Biotechnology [online], 62(1), pp. 27-34. Park https://doi.org/10.1007/s00253-003-1321-8.

      [37] Glover, D.J., Lipps, H.J. and Jans, D.A. (2005) towards safe, non-viral therapeutic gene expression in humans. Nature Reviews Genetics [online], 6(4), pp. 299-310. https://doi.org/10.1038/nrg1577.

      [38] Ramamoorth, M. and Narvekar, A. (2015) Non-viral vectors in gene therapy- an overview. Journal of clinical and diagnostic research: JCDR [online], 9(1), pp. GE01-6. https://doi.org/10.7860/jcdr/2015/10443.5394.

      [39] Cevher, E., Sezer, A.D. and Çağlar, E.Ş. (2012) Gene delivery systems: recent progress in viral and non-viral therapy. [online] INTECH Open Access Publisher.

      [40] Smith, K.R. (2004) Gene Therapy: The Potential Applicability of Gene Transfer Technology to the Human Germline. International journal of medical sciences [online], 1(2), pp. 76-91. https://doi.org/10.7150/ijms.1.76.

      [41] Kamimura, K., Suda, T., Zhang, G. and Liu, D. (2011) Advances in gene delivery systems. Pharmaceutical Medicine [online], 25(5), pp. 293-306. https://doi.org/10.1007/BF03256872.

      [42] Issa, P.C. and MacLaren, R.E. (2012) Non‐viral retinal gene therapy: a review. Clinical & experimental ophthalmology [online], 40(1), pp. 39-47.

      [43] Health and Research Authority (2015) Gene therapy Advisory Committee HRA URL http://www.hra.nhs.uk/resources/applying-to-recs/gene-therapy-advisory-committee-gtac/. https://doi.org/10.1111/j.1442-9071.2011.02649.x.


 

View

Download

Article ID: 7189
 
DOI: 10.14419/ijm.v5i1.7189




Copyright © 2012-2015 Science Publishing Corporation Inc. All rights reserved.